Core Insights - Moderna's stock surged 10% after-hours following a patent settlement worth up to $2.25 billion, with an upfront payment of $950 million, bringing the trading price to $56.67, reflecting a 92.15% year-to-date increase [1] - The patent settlement alleviates legal uncertainties surrounding Moderna's COVID vaccine but significantly impacts its liquidity, with projected cash reserves at the end of 2026 now estimated between $4.5 billion and $5 billion [1] - Despite the positive market reaction, concerns persist regarding Moderna's cash burn rate, which reached $1.873 billion in 2025, and the company's ability to achieve breakeven by 2028 [1] Financial Performance - Moderna's revenue for FY 2025 decreased by 39.23%, attributed to the normalization of COVID vaccine demand, with expectations of zero contribution from the flu vaccine in 2026 [1] - The company is projected to end 2026 with $4.5 billion to $5 billion in cash, down from earlier guidance of $5.5 billion to $6 billion due to the upfront payment related to the patent settlement [1] Market Sentiment - Reddit sentiment towards Moderna has declined from a quarterly average of 50 to a weekly score of 41, despite recent spikes driven by specific catalysts [1] - The stock's performance is closely monitored by traders, with the analyst consensus price target set at $42.25, indicating a potential downside from the current trading price [1]